Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice

xloma.fota.13 shared this article with you from Inoreader Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice Via Head and neck cancers by Byong H. Kang, Noor Momin, Kelly D. Moynihan, Murillo Silva, Yingzhong Li, Darrell J. Irvine, K. Dane Wittrup Following curative immunotherapy of B16F10 tumors, ~60% of mice develop a strong antibody response against cell-surface tumor antigens. Their antisera confer prophylactic protection against intravenous challenge with B16F10 cells, and also cross-react with syngeneic and allogeneic tumor cell lines MC38, EL.4, 4T1, and CT26. We identified the envelope glycoprotein (env) of a murine endogenous retrovirus (ERV) as the antigen accounting for the majority of this humoral response. A systemically administered anti-env monoclonal antibody cloned from such a response protects against tumor challenge, and prophylactic vaccination against the env protein protects a majority of naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells. These results suggest the potential for effective prophylactic vaccination against analogous HERV-K env expressed in numerous human cancers. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.